Nath Bio-Genes Reports FY26 Revenue Growth Amid Profit Dip

Nath Bio-Genes (India) Ltd announced its full-year financial results for FY26, ending March 31, 2026. The company reported robust revenue growth of 19% year-on-year, reaching ₹431.60 Cr. This top-line expansion, however, did not translate to improved profitability. Full-year profit after tax (PAT) declined by 8% to ₹38.40 Cr. Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) remained flat, showing 0% growth at ₹52.50 Cr. In the fourth quarter (Q4FY26), revenue decreased by 7% year-on-year to ₹45.70 Cr. Despite the revenue dip, Q4 EBITDA significantly increased by 109% to ₹6.60 Cr. International operations in Uzbekistan contributed ₹15 Cr to the revenue in FY25-26.

Core Crops and New Segments Drive Revenue

The revenue growth was primarily driven by increased contributions from core crops, including Cotton and Paddy, which now account for 58% of the revenue mix. Maize emerged as a significant high-growth crop within the Non-Cotton, Non-Paddy (NCP) segment, playing a crucial role in the company's performance.

Strategic Expansion into Uzbekistan

Nath Bio-Genes' successful entry and revenue generation in Uzbekistan mark a strategic expansion into international markets. This move diversifies the company's geographic revenue streams and is part of a broader global footprint strategy for the prominent Indian seed company, founded in 1979. Plans for a joint venture focused on cotton seed production in Uzbekistan aim to drive significant future revenue.

Diversification Boosts Resilience

The company's diversification into the NCP segment, which includes crops like maize and vegetables, has become increasingly important. This segment contributed nearly half of the revenue by FY25. This strategic shift aims to de-risk the business from over-reliance on cotton, a segment that has faced challenges, including issues with illegal HTBT seed distribution.

Risks and Analyst Concerns

Challenges for Nath Bio-Genes include a decline in PNS volume, attributed to China export restrictions, although normalization is anticipated. The proliferation of illegal HTBT cotton seeds remains an industry-wide concern, potentially impacting the cotton segment's performance and eroding trust in certified seed systems. In a significant development, MarketsMOJO recently downgraded Nath Bio-Genes to 'Strong Sell', citing weak fundamentals, declining profitability, and reduced institutional investor confidence, which highlight potential financial pressures.

Competitive Landscape

Nath Bio-Genes competes with major Indian and global players such as Mahyco, Syngenta Group, UPL (Advanta India), and Bayer Crop Science. These peers are also heavily invested in research and development and offer a wide range of hybrid seeds, focusing on innovation and expanding market reach.

Investor Focus and Future Outlook

Investors will be monitoring the normalization of PNS volumes following China's export restrictions and assessing the sustained growth of international operations, particularly in Uzbekistan. A key focus will be the company's ability to convert revenue growth into improved profitability and address the FY26 PAT decline. The expansion and performance of the NCP segment, especially maize, will be critical for diversification benefits. Nath Bio-Genes' R&D efforts, market development strategies, and navigation of industry challenges like illegal seed distribution will also be closely watched.